Alterity Therapeutics Limited (ATHE) Balance Sheet

The elevated current ratio is largely a function of the company's cash-heavy asset mix rather than operational efficiency. Investors should monitor the burn rate closely, as the transition from $33.2 million in 2025Q4 to $49.2 million in 2026Q2 implies periodic capital injections that sustain liquidity but dilute existing shareholders.

The absence of retained earnings growth suggests that the company remains entirely dependent on equity financing to offset its operational losses. This structure implies that future clinical milestones will likely be funded through further share issuance, which may continue to pressure the per-share value for long-term holders.

The lack of significant tangible assets confirms that the firm's value is tied entirely to its intellectual property and clinical trial progress. This asset profile warrants caution, as it leaves the company with minimal collateral value should the clinical development of ATH434 fail to meet regulatory expectations.